Pharma / Biotech
This course will give participants the necessary overview of the US Food and Drug Administration's (FDA) current responsibilities, procedures, guidances and regulatory pathways that affect the review and approval of chemical drugs, biologicals, biopharmaceuticals, biosimilars and chemical generics. Using the ICH Common Technical Document (CTD) module format outline, significant Chemistry Manufacturing and Controls (CMC), Nonclinical and Clinical areas will be analyzed and discussed, as a basis for strategic planning for both submitting INDs, NDAs, BLAs, ANDAs, and post-approval supplements, as well as for holding key meetings with the FDA.
Similarities and differences between clinical INDs and market approval dossiers, and between the various market approval dossiers (NDAs, BLAs, and ANDAs) will be discussed. Other topics to be discussed include Fast Track pathway, comparison of chemical generics with biosimilars, FDA's commitments under the User Fee Acts (PDUFA, BsUFA, GDUFA) and FDA's evaluation of industry's performance in meeting its requirements and expectations for review of drug products.
Personnel in the pharmaceutical, biopharmaceutical, biologics and generic drug industry who are involved in preparing FDA submissions (INDs, NDAs, BLAs, ANDAs, post-approval supplements) will find this course to be of particular benefit. Those who need to interact with FDA staff, including Project Managers, Regulatory Affairs, Clinical, Nonclinical, Manufacturing, and Quality personnel, will also find this course extremely useful.
Legal Basis for FDA’s Authority to Regulate Chemical Drugs, Biologics and Biopharmaceuticals
FDA Regulatory Drug Development Review and Approval Process
Meeting with the FDA
Critical Importance of FDA Submissions and Communication during the IND Stage
Critical Importance of the FDA NDA/BLA/ANDA Dossier Preparation
FDA Review and Approval of the NDA/BLA/ANDA Submission
Post-market Approval Submissions and Interactions with the FDA
Navigating the Rich FDA Website Resources
By the end of this course, attendees will:
"I was very impressed with the breadth and depth of knowledge the course director had!" Jennifer, Regulatory Affairs Specialist, Liebel-Flarsheim Company LLC
"My expectations were exceeded with this course. I definitely recommend this for all pharma professionals who are keen to develop their skills in contacting the FDA and to learn how his communication process works." Carlos V., Early Development Manager, Ache Laboratorios Farmaceuticos
"This was an excellent course even for seasoned professionals. This course offers a great overview of the current regulatory environment while also promoting interactions between industry professionals. A great course for professional development." Rachael G., Regulatory Associate, USWorldMeds
"Very good course, interactive and very useful for regulatory professionals. It covered all points from agenda and complied with the objectives. This course helped me to better understand FDA regulations." Maria R., Regulatory Affairs Manager, Probiomed S.A. de C.V.
"I liked the course organization and the material. The communication with the Course Director was very easy." Erica L., Regulatory Affairs Specialist, Probiomed S.A. de C.V.
"John did a great job in keeping us engaged. I most enjoyed the specific examples that were presented within the different topics covered throughout the course. The course content was very thorough, as well as current (updated). This is very important in this field. After attending the course, I have a better understanding on how to prepare/ communicate for FDA interactions. I enjoyed the course very much. John is a great, very knowledgeable instructor!" Daphne, Scientist, Janssen R&D
"This course was pretty intuitive with very good, real-life examples. I like the global perspective incorporated into the presentation slides." Lara N., Director, Regulatory Affairs, Nexgen Pharm
"Very thorough. We covered a large amount of information and the Director was knowledgeable and willing to answer a wide range of questions." Vincent A., Regulatory Affairs Manager, Prestige Brands
"Thoroughly enjoyed the course. Course Director presented and spoke at a good pace to keep your interest peaked. Now have a much better understanding of the submissions process. Knowledge gained in this course will help in my day-to-day work life." Joanne A., Sr. Medical Affairs Coordinator, Bayer
"This was a very well organized course. The pace was perfect and it provided a wealth of information to enhance my ability to file INDs and NDAs. This course was well worth the cost and time away from work." Dr. Sandra W., Research Fellow, Merck
"This course was a great overview of the submission process. Has been very informative, as my company is preparing for an IND filing." Caitlin C., QA Document Control Specialist, Celtaxsys
"The Course Director was an excellent trainer and presenter. The course was fabulous, and I have a very good understanding of the material. The materials, media, internet references will all be put to good use. Thank you for the great experience - I am ready to apply my knowledge!" Stacey H., Sr. QA Associate Regulatory Affairs, Gallus BioPharmaceuticals
"The content of the course was exactly what I was looking for – comprehensive review with practical applications through real-life examples. The knowledge base and personal experience of the instructor and ability to make the course interactive provided an optimal learning environment on a somewhat heavy topic." Jim C., Director, Medical Research, Pfizer
"The course director was incredible and thoroughly versed in the subject matter. Top notch trainer!" Yvonne S., QA Document Manager, Inst. For One World Health
"Very personable Course Director. Held the attention of the class. Very well-organizaed and prepared. Course Notes were well organized. Able to handle questions well and present ‘real-life' experiences." Angela S., Medical Writer, Abbott Laboratories
"Always nice to see actual or mock documents of how things look eCTD, CTD, slides of pre IND meeting examples. Thank you so much, the course was very well done!" Tammy L., Regulatory Affairs Senior Manager, Ultradent Products
"This course gave a great overview and insight into requirements for submissions and working with the FDA. The Course Director's experience provided additional insight that was appreciated!" Amy H., Regulatory Affairs Manager, Cardinal Health
"Very comprehensive and easy to understand!" Carl D., Team Leader of Regulatory Affairs, The Dial Corp.
"The speaker was superior. Seldom do I go to a course where the speaker does not read the overheads word for word. Super, Super, Super!" Chandler W., Manager, Analytical Services, Stability Group
"The Course Director articulated his ideas and the course content in a manner that was concise and interesting. This was the best course and instructor that I have been exposed to thus far. Excellent speaker…great job!" Lynn C., Regulatory Affairs Associate, Biomira
"Great balance of overview of a high amount of material, but also a lot of specific, practical advice." Sean O., QA/Regulatory Compliance, MD Andersen
The course covers all aspects of FDA submissions and communicating with the FDA; all the way from submission of the original IND, through IND amendments, FDA meetings during clinical development, preparation and submission of the market approval dossier (NDA, BLA, ANDA) and maintenance of the market approval.
The course covers FDA concerns and expectations for Chemistry, Manufacturing & Control (CMC), Nonclincal (i.e., animal studies) and Clinical (i.e., human studies).
The course systematically covers all aspects of FDA submissions and communications in three layers. The first layer is a broad overview, and the remaining two layers each dig deeper into understanding the FDA concerns.
We do not yet have a date and time for this event. If you would like to be notified when a date is set, please fill out the form below.
*Valid up to 30 days prior to course date(s). Cannot be combined with other discounts or offers.
The Center for Professional Innovation and Education (CfPIE) provides technical training for Pharmaceutical, Biotech, Medical Device and Skin/Cosmetics professionals. CfPIE offers more than 350 class sessions annually across 80 course titles in multiple formats, such as classroom, on-site and certification programs.
Learn more »
Keep up to date with the latest news from CfPIE, including upcoming courses and events.
Members of participating industry organizations receive special discounts for all our training courses.
© 2001 - 2015 CfPIE, Inc. All Rights Reserved.